U.S. Capital Wealth Advisors LLC Acquires 75,078 Shares of Gilead Sciences, Inc. $GILD

Key Points

• U.S. Capital Wealth Advisors LLC increased its stake in Gilead Sciences by 1,220.8% during the 2nd quarter, acquiring an additional 75,078 shares, bringing its total holdings to 81,228 shares valued at approximately $9 million.
• Insider transactions revealed that CFO Andrew D. Dickinson and Johanna Mercier sold shares on September 15, collectively amounting to approximately $624,000, indicating a 1.54% and 2.58% decrease in their ownership, respectively.
• Analysts have recently upgraded Gilead's stock ratings, with a consensus target price now standing at $117.17, reflecting a strong buy sentiment from multiple firms.

U.S. Capital Wealth Advisors LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1,220.8% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 81,228 shares of the biopharmaceutical company's stock after purchasing an additional 75,078 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in Gilead Sciences were worth $9,006,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in Gilead Sciences in the 4th quarter worth $215,000. North Star Asset Management Inc. bought a new position in Gilead Sciences in the 4th quarter worth $201,000. Formidable Asset Management LLC bought a new position in Gilead Sciences in the 4th quarter worth $212,000. Finally, Toronto Dominion Bank raised its holdings in Gilead Sciences by 11.0% in the 4th quarter. Toronto Dominion Bank now owns 710,523 shares of the biopharmaceutical company's stock worth $65,631,000 after purchasing an additional 70,551 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 1.4%

Shares of NASDAQ:GILD traded down $1.60 during trading hours on Monday, hitting $112.49. 7,258,168 shares of the company's stock traded hands, compared to its average volume of 6,195,682. Gilead Sciences, Inc. has a 1 year low of $81.83 and a 1 year high of $121.83. The business has a fifty day moving average price of $114.11 and a 200-day moving average price of $109.95. The firm has a market capitalization of $139.58 billion, a P/E ratio of 22.41, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the business earned $2.01 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend is Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares of the company's stock, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the sale, the chief executive officer directly owned 595,725 shares of the company's stock, valued at $67,692,231.75. This represents a 1.65% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,000 shares of company stock valued at $9,390,030. Corporate insiders own 0.27% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on GILD. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Royal Bank Of Canada raised their price target on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a report on Friday, September 5th. Needham & Company LLC raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a report on Friday, July 25th. Finally, Daiwa Capital Markets raised Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a report on Tuesday, August 19th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $117.17.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.